The natriuretic effect of GLP-1R agonists along with the effects of these drugs on the conventional risk factors for DN (such as hyperglycemia, hypertension and obesity) may represent the most relevant mechanisms underlying their antialbuminuric effect (Figure 1b). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.